{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:53:30Z","timestamp":1793116410645,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Chiglitazar is a novel peroxisome proliferator\u2010activated receptor pan\u2010agonist regulating glucose and lipid metabolism. The RECAM study aimed to evaluate the efficacy and safety of chiglitazar add\u2010on therapy to metformin in patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      In this randomised, double\u2010blind, phase III trial (NCT04807348), 533 patients with T2DM inadequately controlled by metformin were randomly assigned in a 1:1:1 ratio to receive chiglitazar 32\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009178), chiglitazar 48\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009177), or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009178) for 24\u2009weeks, in addition to metformin. The primary endpoint was the change in glycosylated haemoglobin (HbA1c) from baseline to week 24.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At week 24, the least squares mean changes in HbA1c were \u22120.91% (95% CI: \u22121.03% to \u22120.79%) in the chiglitazar 32\u2009mg group, \u22121.14% (95% CI: \u22121.26% to \u22121.02%) in the chiglitazar 48\u2009mg group, and \u22120.49% (95% CI: \u22120.62% to \u22120.36%) in the placebo group. Both chiglitazar 32\u2009mg and 48\u2009mg significantly reduced HbA1c compared to placebo (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with the reduction being greater in the 48\u2009mg group than in the 32\u2009mg group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). Chiglitazar significantly improved fasting plasma glucose and 2\u2010h postprandial glucose while reducing triglyceride and free fatty acid levels and increasing high\u2010density lipoprotein cholesterol levels. The incidence of adverse events was comparable across groups, with a slight increase in weight gain and mild oedema observed in the chiglitazar groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Chiglitazar combined with metformin significantly improves glycaemic control and lipid metabolism in Chinese patients with T2DM who are inadequately managed with metformin and have a favourable safety profile.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link>\n                      (NCT04807348).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70009","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:19:52Z","timestamp":1755847192000},"page":"6243-6253","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of chiglitazar add\u2010on to metformin in type 2 diabetes mellitus (\n                    <scp>RECAM<\/scp>\n                    study)"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4928-9418","authenticated-orcid":false,"given":"Leili","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-1598","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Jinan Central Hospital  Jinan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The Fourth Affiliated Hospital of Harbin Medical University  Harbin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Panjin Liaoyou Baoshi Flower Hospital  Panjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Yueyang People's Hospital  Yueyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Nanjing First Hospital  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Chenzhou First People's Hospital  Chenzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Yifu Hospital Affiliated of Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Zhuzhou Central Hospital  Zhuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyan","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Huaihe Hospital of Henan University  Kaifeng China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiang","family":"Cao","sequence":"additional","affiliation":[{"name":"Chipscreen Biosciences Co., Ltd.  Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[{"name":"Chipscreen Biosciences Co., Ltd.  Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Li","sequence":"additional","affiliation":[{"name":"Chengdu Chipscreen Pharmaceutical Co., Ltd.  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianping","family":"Lu","sequence":"additional","affiliation":[{"name":"Chipscreen Biosciences Co., Ltd.  Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the RECAM Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m997"},{"key":"e_1_2_9_3_1","volume-title":"IDF Diabetes Atlas","author":"Magliano DJ","year":"2021"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12801"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0227"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1248614"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl524"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2152"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.733428"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.37"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.03.012"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-0991-1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1301093"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01648-1"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2021.03.019"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2021.02.027"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00779-4"},{"issue":"5","key":"e_1_2_9_19_1","first-page":"334","article-title":"Efficacy and safety of chiglitazar in type 2 diabetes: a multi\u2010center, randomized, double\u2010blind, and parallel group clinical trial","volume":"11","author":"Xiaofeng L","year":"2019","journal-title":"Chin J Diabetes Mellit"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.9.5.406"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.668"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15192"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2105"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2022.0387"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565030-00005"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30105-0"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01803-5"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59390-z"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1270-y"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70009","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:22:50Z","timestamp":1771309370000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/dom.70009"],"URL":"https:\/\/doi.org\/10.1111\/dom.70009","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70009\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70009\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70009\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70009\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70009\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70009\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70009\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70009\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70009\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70009\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2025-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}